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Abstract
Mixed cryoglobulinemia (MC), type II and type III, refers to the presence of circulating
cryoprecipitable immune complexes in the serum and manifests clinically by a classical triad of
purpura, weakness and arthralgias. It is considered to be a rare disorder, but its true prevalence
remains unknown. The disease is more common in Southern Europe than in Northern Europe or
Northern America. The prevalence of 'essential' MC is reported as approximately 1:100,000 (with
a female-to-male ratio 3:1), but this term is now used to refer to a minority of MC patients only.
MC is characterized by variable organ involvement including skin lesions (orthostatic purpura,
ulcers), chronic hepatitis, membranoproliferative glomerulonephritis, peripheral neuropathy,
diffuse vasculitis, and, less frequently, interstitial lung involvement and endocrine disorders. Some
patients may develop lymphatic and hepatic malignancies, usually as a late complication. MC may be
associated with numerous infectious or immunological diseases. When isolated, MC may represent
a distinct disease, the so-called 'essential' MC. The etiopathogenesis of MC is not completely
understood. Hepatitis C virus (HCV) infection is suggested to play a causative role, with the
contribution of genetic and/or environmental factors. Moreover, MC may be associated with other
infectious agents or immunological disorders, such as human immunodeficiency virus (HIV)
infection or primary Sjögren's syndrome. Diagnosis is based on clinical and laboratory findings.
Circulating mixed cryoglobulins, low C4 levels and orthostatic skin purpura are the hallmarks of
the disease. Leukocytoclastic vasculitis involving medium- and, more often, small-sized blood
vessels is the typical pathological finding, easily detectable by means of skin biopsy of recent
vasculitic lesions. Differential diagnoses include a wide range of systemic, infectious and neoplastic
disorders, mainly autoimmune hepatitis, Sjögren's syndrome, polyarthritis, and B-cell lymphomas.
The first-line treatment of MC should focus on eradication of HCV by combined interferon-
ribavirin treatment. Pathogenetic treatments (immunosuppressors, corticosteroids, and/or
plasmapheresis) should be tailored to each patient according to the progression and severity of the
clinical manifestations. Long-term monitoring is recommended in all MC patients to assure timely
diagnosis and treatment of the life-threatening complications. The overall prognosis is poorer in
patients with renal disease, liver failure, lymphoproliferative disease and malignancies.
Disease name and synonyms
Mixed cryoglobulinemia (type II or type III), cryoglob-
ulinemic vasculitis.
Definition
The term cryoglobulinemia refers to the presence in the
serum of one (monoclonal cryoimmunoglobulinemia) or
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which precipitate at temperatures below 37°C and re-dis-
solve on re-warming [1,2]. This is an in vitro phenomenon
(Fig. 1), the actual mechanism(s) of cryoprecipitation
remains obscure, it could be secondary to intrinsic charac-
teristics of both mono- and polyclonal immunoglobulin
(Ig) components, it can be caused as well by the interac-
tion among single components of the cryoprecipitate [1-
14].
Cryoglobulinemia is usually classified into three sub-
groups [4] according to Ig composition (Table 1): type I
cryoglobulinemia is composed of only one isotype or sub-
class of immunoglobulin. Both type II and type III mixed
cryoglobulins are immune complexes composed of poly-
clonal IgGs, the autoantigens, and mono- or polyclonal
IgMs, respectively; the IgMs are the corresponding autoan-
tibodies with rheumatoid factor (RF) activity [3-6]. With
more sensitive methodologies, i.e. immunoblotting or 2-
dimensional polyacrylamide gel electrophoresis, type II
mixed cryoglobulins frequently shows a microheteroge-
neous composition; in particular, oligoclonal IgM or a
mixture of polyclonal and monoclonal IgM can be
detected [3]. This particular serological subset, termed
type II-III mixed cryoglobulinemia (MC), could represent
an intermediate, evolutive state from type III to type II
MC. Moreover, type II-III MC could fit together the most
recent molecular studies showing the presence of oligo-
clonal B-lymphocyte proliferation in the liver and bone
marrow biopsies from MC patients [3]. In two third of
type II MC, a cross-idiotype WA monoclonal RF (firstly
isolated from the serum of a patient with Waldenström's
macroglobulinemia) has been demonstrated [14].
Type I cryoglobulinemia is almost invariably associated
with well-known hematological disorders and is fre-
quently asymptomatic per se; similarly, circulating mixed
cryoglobulins are commonly detected in a great number
of infectious or systemic disorders [1-14]. On the con-
trary, 'essential' MC represents a distinct disorder [3-6],
which can be classified among systemic vasculitides [3-
10]. Cryoglobulinemic vasculitis (Fig. 2) is secondary to
vascular deposition of circulating immune-complexes,
mainly cryoglobulins, and complement, with the possible
contribution of both hemorheological and local factors
[3-6]. Due to its clinical and histological features, MC is
classified in the subgroup of small vessel systemic vascu-
litides, which also includes cutaneous leukocytoclastic
vasculitis and Henoch-Schonlein purpura [3,10].
The leukocytoclastic vasculitis is the histopathological
hallmark of MC (Fig. 2). It may involve small- and
medium-sized vessels and may be responsible for multi-
ple organ involvement. The term 'cryoglobulinemic vas-
culitis' is frequently used as synonym; it better focus on
the typical histopathological alterations responsible for
cutaneous and visceral organ involvement [3,10].
Epidemiology
The prevalence of MC presents great geographic heteroge-
neity; the disease is more common in Southern Europe
than in Northern Europe or Northern America [3-13]. It is
considered to be a rare disorder, however, yet there are no
adequate epidemiological studies regarding its overall
prevalence. Given its clinical polymorphism, a single
manifestation (skin vasculitis, hepatitis, nephritis, periph-
eral neuropathy, etc.) is often the only apparent or clini-
cally predominant feature, so that MC patients are often
referred to different specialties (Fig. 3). A correct diagnosis
might thus be delayed or overlooked entirely. Conse-
quently, the actual prevalence of MC might be underesti-
mated.
For the same reasons, the clinical pattern of the MC syn-
drome may vary largely among patients series referred to
different tertiary care facilities [3,6,8-14] (Fig. 3).
Cryocrit determination in a patient with mixed cryoglob-ulinemia (MC)Figure 1
Cryocrit determination in a patient with mixed cry-
oglobulinemia (MC). Graduated glass tubes with serum 
sample from cryoglobulinemic patient at different time inter-
vals: 0- soon after serum separation from the whole blood 
sample (at least 20 ml of whole blood); 7- after 7 days at 
+4°C; and cryocrit measurement after serum centrifugation, 
always at +4°C. (modified from [24], Ferri C et al, Sem 
Arthritis Rheum 2004, 33:355–74.).Page 2 of 17
(page number not for citation purposes)
Orphanet Journal of Rare Diseases 2008, 3:25 http://www.ojrd.com/content/3/1/25It has been estimated that low levels of circulating mixed
cryoglobulins can be detected in over 50% of HCV-
infected individuals, while overt cryoglobulinemic syn-
drome develops in about 5% [3,15,16]. Because of the
wide diffusion of HCV infection worldwide, a growing
incidence of HCV-related MC can be expected, especially
in underdeveloped countries where HCV in the general
population is rather prevalent [3,17].
The prevalence of 'essential' MC is reported as approxi-
mately 1:100,000 but this term is now referred to a minor-
ity of MC patients. The female-to-male ratio is 3:1.
Clinical description
According to its first description [5], MC syndrome is
characterized clinically by a triad -purpura, weakness,
Table 1: Classification and clinico-pathological characteristics of different cryoglobulinemias.
Composition Pathological findings Clinical associations
Type I cryoglobulinemia monoclonal Ig, mainly IgG, or IgM, or IgA
self-aggregation through Fc fragment of Ig
tissue histological alterations of 
underlying disorder
-lymphoproliferative disorders: 
MM, WM, CLL, B-cell NHL
Type II
mixed cryoglobulinemia
monoclonal IgM (or IgG, or IgA) with RF 
activity (often cross-idiotype WA-mRF) 
and polyclonal Ig (mainly IgG)
-leukocytoclastic vasculitis
-B-lymphocyte expansion with 
tissue infiltrates
-infections (mainly HCV)
-autoimmune/lymphoproliferative 
disorders
-rarely 'essential'
Type II–III
mixed cryoglobulinemia
oligoclonal IgM RF or mixture of poly/
monoclonal IgM
(often cross-idiotype WA-mRF)
-leukocytoclastic vasculitis
-B-lymphocyte expansion with 
tissue infiltrates
-infections (mainly HCV)
-autoimmune/lymphoproliferative 
disorders
-rarely 'essential'
Type III
mixed cryoglobulinemia
polyclonal mixed Ig (all isotypes) with RF 
activity of one polyclonal component 
(usually IgM)
-leukocytoclastic vasculitis
-B-lymphocyte expansion with 
tissue infiltrates
-infections (mainly HCV)
-more often autoimmune disorders
-rarely 'essential'
lymphoproliferative disorders: MM (multiple myeloma), WM (Waldenstrom's macroglobulinemia), chronic lymphocytic leukemia), B-cell non-
Hodgkin's lymphoma;
Ig: immunoglobulin; RF: rheumatoid factor; HCV: hepatitis C virus
Cutaneous manifestations of mixed cryoglobulinemia (MC)Figur  2
Cutaneous manifestations of mixed cryoglobulinemia 
(MC). (a) recent onset orthostatic purpura; at this stage the 
histopathological evaluation shows (b) the classical necrotiz-
ing leukocytoclastic vasculitis characterized by diffuse fibri-
noid necrosis and disintegrated neutrophil permeation of the 
vessel walls; (c) symmetrical hyperpigmentation of the skin 
on the legs after repeated episodes of purpura; both orthos-
tatic purpura and these permanent ochraceous lesions repre-
sent the typical skin manifestations of MC; (d) severe 
vasculitic manifestation; (e) wide skin ulcer, often resistant to 
treatment.
Different referrals of patients with mixed cryoglobulinemia (MC)Figu  3
Different referrals of patients with mixed cryoglob-
ulinemia (MC). Given its clinical polymorphism, the MC 
syndrome may develop through different, often unpredicta-
ble symptoms. Consequently, MC patients may be referred 
to different specialties according to prevalent or apparently 
unique clinical manifestation, such as membranoproliferative 
glomerulonephritis (MPGN) or purpuric skin lesions. Patients 
with very mild manifestations, often arthralgias and/or serum 
rheumatoid factor (RF) positivity, are generally referred to 
rheumatologic clinic.Page 3 of 17
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including chronic hepatitis, membranoproliferative
glomerulonephritis (MPGN), peripheral neuropathy, skin
ulcers, diffuse vasculitis, and, less frequently, by lym-
phatic and hepatic malignancies [3-12,17-23]. The clini-
cal pattern of cryoglobulinemic vasculitis is comparable
in patients with type II or type III MC [3]. The prevalence
of MC manifestations reported in Table 2 regards an Ital-
ian patient population referred to our university-based
division of rheumatology. Patients' recruitment at differ-
ent specialist centers, as well as the racial composition
among patients' series may be responsible for the variable
prevalence of MC symptoms reported in the literature [3-
10,14].
The presenting symptoms of MC largely vary among
patients with cryoglobulinemia. At the initial observation,
MC shows different clinico-serological patterns, varying
from apparently isolated serum mixed cryoglobulins to
complete cryoglobulinemic syndrome (Fig. 4). This is a
combination of serological findings (mixed cryoglobulins
with RF activity and frequent low C4) and clinico-patho-
logical features (purpura, leukocytoclastic vasculitis with
multiple organ involvement) [6-10,14,24,25]. Asympto-
matic serum mixed cryoglobulins can be found in some
chronically HCV-infected individuals [3,15,16]; a condi-
tion that may precede for years or decades the clinical
onset of the disease. On the other hand, some patients
show typical cryoglobulinemic syndrome, without serum
cryoglobulins, the hallmark of the disease (Fig. 4). This is
generally a transient phenomenon due to the wide varia-
bility of the percentage of cryoprecipitable immune-com-
plex [3,26]. Repeated cryoglobulin determinations are
necessary for a correct diagnosis in these subjects.
Skin lesions represent the most frequent manifestations
of the MC [6-10,14,24,25]. Orthostatic purpura is gener-
ally intermittent, the dimension and diffusion of purpuric
lesions largely varied, from sporadic isolated petechias to
severe vasculitic lesions, often complicated by torpid
ulcers of the legs and malleolar areas (Fig. 2). In a signifi-
cant proportion of patients, repeated episodes of purpura
may lead to stable, often confluent areas of ochreous col-
oration on the legs (Fig. 2). Cutaneous manifestations, in
particular orthostatic purpura and ulcers, are the direct
consequence of vasculitic alterations with the possible
contributions of various co-factors, in particular chronic
venous insufficiency, physical stress, mainly the pro-
longed standing, and/or muggy weather. In addition, the
contribution of hemorheological disturbances due to
high cryocrit levels may also be taken in account [27]. In
this respect, the purpuric outbreaks are frequently
observed late in the afternoon when highest cryocrit levels
Table 2: Demographic, clinico-serological and virological 
features of 250 mixed cryoglobulinemia (MC) patients*.
Clinical features
Age at disease onset, mean ± SD yrs (range) 54 ± 13 (29–72)
Female/Male ratio 3
Disease duration, mean ± SD years (range) 12 ± 10 (1–40)
Purpura 98%
Weakness 98%
Arthralgias 91%
Arthritis (non-erosive) 8%
Raynaud's phenomenon 32%
Sicca syndrome 51%
Peripheral neuropathy 81%
Renal involvement** 31%
Liver involvement 73%
B-cell non-Hodgkin's lymphoma 11%
Hepatocellular carcinoma 3%
Cryocrit, mean ± SD % 4.4 ± 12
Type II/type III mixed cryoglobulins 2/1
C3, mean ± SD mg/dl (normal 60–130) 93 ± 30
C4, mean ± SD mg/dl (normal 20–55) 10 ± 12
Antinuclear antibodies 30%
Antimitochondrial antibodies 9%
Anti-smooth muscle antibodies 18%
Anti-extractable nuclear antigen antibodies 8%
anti-HCV Ab ± HCV RNA, % 92%
Anti-HBV antibodies 32%
HBsAg 1%
* evaluated at the end of the patients' follow-up
**invariably membranoproliferative glomerulonephritis
Relationship between cryoglobulin detection and overt mixed cryoglobulin mia (MC) syndromeFigure 4
Relationship between cryoglobulin detection and 
overt mixed cryoglobulinemia (MC) syndrome. (1) 
Definite MC syndrome (or cryoglobulinemic vasculitis) is a 
combination of serological findings (mixed cryoglobulins with 
RF activity and frequent low C4) and typical clinico-patholog-
ical features (purpura, leukocytoclastic vasculitis, and fre-
quent multiple organ involvement); see also Table 3. 
However, incomplete MC syndrome can be observed at any 
time during the natural history of the disease; (2) Isolated 
serological alterations may be detected in the early stages of 
the disease or during the clinical remission; on the contrary; 
(3) the absence of serum cryoglobulins in patients with overt 
MC syndrome may be a transient phenomenon due to the 
wide variability of the percentage of cryoprecipitable 
immune-complex during the natural history of the disease or, 
less frequently, to a switching from 'benign' B-cell lympho-
proliferation to malignant lymphoma.Page 4 of 17
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longed standing [24].
MC patients commonly report arthralgias, while clear
clinical signs of arthritis (usually mild, non-erosive oli-
goarthritis) are relatively rare [11,12,25,28]
Almost half MC patients complain of xerostomia and
xerophthalmia, however, only a few cases meet the cur-
rent criteria for the classification of primary Sjogren's syn-
drome (see 'differential diagnosis') [11,12,25].
Peripheral neuropathy may frequently complicate the
clinical course of the MC, in the majority of cases as mild
sensory neuritis [24,25,29,30]. The common symptoms
are paresthesias with painful and/or burning sensations in
the lower limbs, often with nocturnal exacerbation. The
patient quality of life may be severely compromised
because of the chronicity of these symptoms along with
their scarce sensibility to therapeutic attempts. In a minor-
ity of cases the peripheral neuropathy may be complicated
by severe sensory-motor manifestations, which usually
appeared abruptly, often as asymmetric mononeuritis; in
some patients, it may complicate the alpha-interferon
treatment, possibly in predisposed subjects [29-33]. Dys-
arthria and hemiplegia expression of central nervous sys-
tem involvement are rarely reported [25,34]; it is often
difficult to distinguish these symptoms from the most
common atherosclerotic manifestations.
Since HCV infection represents the underlying disorder of
the MC in the vast majority of cases, overt chronic hepa-
titis, generally with mild-to-moderate clinical course, can
be observed at any time during the natural history of the
disease [24,25]. Chronic hepatitis was found in a great
number of patients (Table 2), evolving to cirrhosis in 1/4,
while only 7 patients developed hepatocellular carci-
noma. In few cases, especially in combination with renal
involvement, liver involvement became a life-threatening
complication. On the whole, the clinical course and the
prognostic value of this manifestation seem to be less
severe if compared to HCV-related chronic hepatitis with-
out MC syndrome [24,25]; similarly, hepatocellular carci-
noma less frequently complicates MC syndrome
compared to the whole population of HCV-positive indi-
viduals [24,25]. These differences are quite intriguing, but
very difficult to fully explain. It is possible that the light
consumption of alcohol and/or the relatively low preva-
lence of HCV genotype 1b [24,25] may explain, at least in
part, the rather benign clinical course of liver involvement
and its scarce prognostic relevance in MC series.
Membranoproliferative glomerulonephritis type 1 is
another important organ involvement, which may
severely affect the prognosis and survival of the disease
[24,25,34-37]. MC-related nephropathy is a typical
immune-complex-mediated glomerulonephritis,
although other immunological mechanisms have also
been hypothesized [24,25,38,39].
Widespread vasculitis involving medium-small sized
arteries, capillaries and venules with multiple organ
involvement may develop in a small proportion of
patients [3,6,10,24,25,40]. This extremely severe compli-
cation may involve the skin, kidney, lungs, central nerv-
ous system, and gastrointestinal tract. In rare cases
intestinal vasculitis may suddenly complicate the disease,
often in patients with renal and/or liver involvement; pain
simulating an acute abdomen is the presenting symptom
of intestinal vasculitis. A timely diagnosis and aggressive
steroid treatment are necessary for this life-threatening
complication.
Interstitial lung involvement has been anecdotally
observed in MC syndrome as well as in patients with iso-
lated HCV infection [3,25,41-43]. Almost invariably, lung
involvement in MC is characterized by subclinical alveoli-
tis, as demonstrated by means of bronco-alveolar lavage
in unselected patient series [44]; this condition may pre-
dispose to harmful infectious complications and, in rare
cases, it may lead to clinically evident interstitial lung
fibrosis. The hyperviscosity syndrome, due to high levels
of serum cryoglobulins is another rare clinical manifesta-
tion of MC [27]. Generally, there was no relationship
between the severity of clinical symptoms, such as
glomerulonephritis, skin ulcers, or diffuse vasculitis and
the serum levels of cryoglobulins and/or hemolytic com-
plement [3,24,25]. Low complement activity is almost
invariably detectable in MC, with the typical pattern of
low or undetectable C4 and normal or relatively normal
C3 serum levels, regardless the disease activity (Table 2).
Moreover, in vitro consumption of complement can be
also observed due to the anti-complement activity of
some cryoimmunoglobulins [3]. Of interest, a sudden
increase in C4, raised to abnormally high levels, can be
observed in MC patients developing a B-cell lymphoma
[45]. The lack of correlation between circulating cryoglob-
ulin levels and the severity/activity of MC manifestations
might be explained on the basis of different hypotheses:
the pathogenic role of other non-cryoprecipitable
immune-complexes, their intrinsic capacity to activate the
complement, and/or the in situ formation of immune-
complexes, with a relative concentration of HCV virions
[3,14,24,25].
Some endocrinological disorders are significantly more
frequent in MC patients compared to the general popula-
tion [3,12,13,24,25,46-50]. The most common thyroid
disorders are autoimmune thyroiditis, subclinical
hypothyroidism, and thyroid cancer; while hyperthy-Page 5 of 17
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tion of interferon treatment [51-54]. Moreover, a
statistically increased incidence of diabetes mellitus has
been observed in HCV-positive patients with and without
MC syndrome compared to the general population [55-
57]. Finally, HCV-positive males with or without cry-
oglobulinemic vasculitis may develop erectile dysfunc-
tion, attributable to hormonal and/or neuro-vascular
alterations [49].
B-cell lymphoma is the most frequent neoplastic manifes-
tation complicating MC, often as late manifestation of the
MC syndrome [58-65]. This complication may be related
to peripheral B-lymphocyte expansion and to lymphoid
infiltrates observed in the liver and bone marrow of MC
patients [19,39,58,59]. In particular, these infiltrates have
been regarded by some authors as "early lymphomas",
since they are sustained by lymphoid components indis-
tinguishable from those of B-cell chronic lymphocytic
leukemia/small lymphocytic lymphoma (B-CLL) and
immunocytoma (Ic) [3,12,25,59]. However, unlike frank
malignant lymphomas, they tend to remain unmodified
for years or even decades and are followed by overt lym-
phoid tumors in about 10% of cases [3]. These character-
istics justify the proposed term of "monotypic
lymphoproliferative disorder of undetermined signifi-
cance (MLDUS)" [3,12,25,59]. Interestingly enough, type
II MC-related MLDUS has its highest incidence in the
same geographic areas where about 30% of patients with
'idiopathic' B-cell lymphomas also display HCV-positiv-
ity, and where an increased prevalence of HCV genotype
2a/c has been observed in both MC and lymphomas
[3,12,25,59]. The type II MC-associated MLDUS presents
two main pathological patterns; namely, the B-CLL-like
and the Ic-like [3,12,25,59]. In the clinical practice, it is
not rare to observe the appearance of malignant B-cell
lymphomas in patients with mild MC clinical course,
sometimes unexpectedly during a routine evaluation. It is
possible to observe a sudden decrease or disappearance of
serum cryoglobulins and RF, sometimes associated with
abnormally high levels of C4, as presenting symptom of
complicating B-cell malignancy [40].
Other neoplastic manifestations, i.e. hepatocellular carci-
noma or papillary thyroid cancer, are less frequently
observed [3,11,24,50,59]. In this light, the MC can be
regarded as a pre-neoplastic disorder [61]; consequently,
a careful clinical monitoring is recommendable, even in
the presence of mild MC syndrome [3,11].
Etiopathogenesis
Since the first description of MC syndrome [5], chronic
hepatitis has been reported as frequent manifestation
appearing during the clinical course of the disease [3-
6,11,24]; therefore, a possible role for hepatotropic
viruses in the pathogenesis of the disease has long been
suggested [3,12]. A role for hepatitis B virus (HBV) has
been firstly investigated [66]; however, HBV viremia is
rarely recorded, while anti-HBV antibodies largely varied
among different MC patient populations [3]. It can be
estimated that HBV can represent a causative factor of MC
in less than 5% of individuals (Fig. 5).
Soon after the discovery of hepatitis C virus (HCV) as the
major etiologic agent of non-A-non-B chronic hepatitis
[67], a possible role of HCV infection in MC was proposed
independently by two pioneering reports [68,69] showing
a significantly higher prevalence of serum anti-HCV anti-
bodies compared to the general population. This hypoth-
esis was definitely demonstrated in 1991, when the
presence of HCV RNA was detected by means of polymer-
ase chain reaction (PCR) in 86% of Italian MC patients
[70]. Successively, an increasingly number of studies
including clinico-epidemiological observations, as well as
both histopathological and virological investigations
(HCV RNA detection by PCR and/or in situ hybridization)
have been definitely established the preeminent role of
HCV in the pathogenesis of MC [8-14,21,25,59,71-76].
The prevalence of serum anti-HCV antibodies and/or
HCV RNA in MC patients ranged from 70% to almost
100% among different patient populations [3,11-13,25].
Given the striking association between MC and HCV
Schematic representation of different clinical and virological subsets of mixed cryoglobulinemia (MC) syndromeFigure 5
Schematic representation of different clinical and 
virological subsets of mixed cryoglobulinemia (MC) 
syndrome. 1) 'essential' MC (EMC); 2) and 3) 'essential' MC 
and HCV-associated MC syndrome in the setting of definite 
autoimmune-lymphoproliferative disorders (ALD), such as 
autoimmune hepatitis, Sjögren's syndrome or B-cell lympho-
mas; 4) the most frequent subset of HCV-associated MC syn-
drome; 5) MC associated with other infectious agents such as 
hepatitis B virus (HBV). (modified from [12,13]: Ferri C et al, 
B-cells and mixed cryoglobulinemia. Autoimm Rev 2007, 7: 
114–20; Mascia MT et al, Non HCV-related mixed cryoglob-
ulinemia. Dig Liver Dis 2007, 39: S61–4.).Page 6 of 17
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of MC patients (in Italy <5%, Fig. 5) [3,11-13,25].
Because of the frequent association between MC and
HCV, the behavior of MC is closely linked to the natural
history of HCV chronic infection [3,11-13,24,25]. How-
ever, MC is also the result of concomitant genetic and/or
environmental factors, which remain largely unknown
(Fig. 6). HCV has been recognized to be both a hepato-
and lymphotropic virus, as suggested by the presence of
active or latent viral replication in the peripheral lym-
phocytes of patients with type C hepatitis or MC
[3,73,77]. HCV is an RNA virus without reverse tras-
criptase activity; therefore viral genome cannot integrate
in the host genome [63]. Probably, HCV may exert a
chronic stimulus of the immune-system, through differ-
ent viral proteins such as core protein [9,22,63]. Chronic
stimulation of the lymphatic system exerted through viral
epitopes, autoantigen production, and/or molecular
mimicry mechanism has been suggested by the presence,
in HCV-positive patients, of anti-GOR antibodies, which
are cross-reactive autoantibodies directed to both HCV
core and a nuclear antigen named GOR [3,59,63]. Other
Authors suggested that HCV, in association with very low-
density lipoprotein (VLDL), might induce a T-independ-
ent primordial B-cell population producing monoclonal
immunoglobulin with WA idiotype [14]. In turn, HCV-
VLDL complexes may trigger RF production as conse-
quence of somatic mutations of WA clones; the possible
evolution to B-cell lymphomas might be the consequence
of the accumulation of stochastic genetic aberrations [59].
Chronic stimulation of the B-cell by HCV epitopes may
produce the expansion of some B-cell subpopulations
with favorable and/or dominant genetic characteristics.
This hypothesis recalls the pathogenetic role of Helico-
bacter pylori in MALT lymphoma of the stomach, for which
different evolutive phases are requested [59].
Another important pathogenetic factor is the interaction
between HCV E2 protein and CD81 molecule, a quite
ubiquitary tetraspannin present on B-cells surface [78];
the consequence may be the strong and sustained polyclo-
nal stimulation of B-cell compartment (Fig. 6). A follow-
ing pathogenetic step of HCV-related autoimmune-
lymphoproliferative disorders may be the t [14,18] trans-
location observed in B-cells of HCV-infected individuals
[63,79]. Even if not definitely confirmed [80,81], the t
[14,18] translocation might lead to abnormally elevated
expression of Bcl-2 protein with consequent inhibition of
apoptosis and abnormal B-cell survival. Interestingly, the
relevant prevalence of t [14,18] translocation in patients
with only type C hepatitis (about 37–38%), become par-
ticularly high in patients with HCV-related cryoglobuline-
mic syndrome, ranging 85% in type II MC [63]. It is
possible to hypothesize that during chronic HCV infec-
tion, several factors (including the interaction between
HCV E2 protein and CD81 molecule, the high viral varia-
bility, and the persistent infection of both hepatic and
lymphatic cells) may favor a sustained and strong B-cell
Etiopathogenesis of mixed cryoglobulinemia (MC) syndromeFigure 6
Etiopathogenesis of mixed cryoglobulinemia (MC) 
syndrome. The figure summarizes the etiopathogenetic cas-
cade of MC and other HCV-related disorders. This is proba-
bly a multifactorial and multistep process: the remote events 
include some infectious agents, mainly HCV, predisposing 
host factors, and possible unknown environmental/toxic trig-
gers. Viral antigens (for example HCV core, envelop E2, NS3, 
NS4, NS5A proteins) may exert a chronic stimulus on the 
host immune- system through specific lymphocyte receptors, 
such as CD81 that may interact with the viral E2. Predispos-
ing host factors may include particular HLA alleles, metabolic 
and hormonal conditions. The main consequence is a 'benign' 
B-cell proliferation with a variety of autoantibody produc-
tion, among which rheumatoid factor (RF), and cryo- and 
non-cryoprecipitable immune-complexes (IC). These sero-
logical alterations may be correlated with different organ- 
and non-organ-specific autoimmune disorders, including the 
MC syndrome (or cryoglobulinemic vasculitis). Moreover, 
the activation of Bcl2 proto-oncogene, responsible for pro-
longed B-cell survival, may be a predisposing condition to 
other genetic aberrations, which may lead to frank B-cell 
lymphomas and other malignancies. The appearance of malig-
nant neoplasias can be observed in a small but significant per-
centage of patients, usually as late complication. Both 
immunological and neoplastic disorders show a clinico-sero-
logical and pathological overlap. Often, autoimmune organ-
specific manifestations may evolve to systemic conditions, 
and less frequently to malignancies. Conversely, it is not rare 
that patients with malignancies may develop one or more 
autoimmune manifestations. In this scenario, MC syndrome 
represents a crossing road between autoimmune and neo-
plastic disorders. (modified from [11,12]: Ferri C et al, HCV-
related autoimmune and neoplastic disorders: the HCV syn-
drome. Dig Liver Dis 2007, 39: S13–21; Ferri C et al, B-cells 
and mixed cryoglobulinemia. Autoimm Rev 2007, 7: 114–20.).Page 7 of 17
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rition of t [14,18] translocation and Bcl-2 overexpression;
the consequent B-lymphocyte expansion is responsible
for autoantibody production, including the cryoglobulins
[3,11,12,63,77-79]. In addition, the prolonged B cell sur-
vival may represent a predisposing condition for further
genetic aberrations, which may lead to frank B-cell malig-
nancy as late complication of MC syndrome
[11,20,24,82].
Of interest, HCV-driven lymphoproliferation may explain
the pathogenetic role of HCV infection also in 'idiopathic'
B-cell lymphomas [11,59,64,65,80]. This association was
firstly described in unselected Italian patients with 'idio-
pathic' B-cell lymphomas [64] and successively confirmed
by different epidemiological and laboratory studies,
mainly in the same geographical areas where HCV-associ-
ated MC is commonly found [65].
Given its biological characteristics, HCV may be involved
in a wide number of autoimmune and lymphoprolifera-
tive disorders [3,11,12,63,77-79]. Fig. 6 summarizes the
main causative factors -infectious, toxic, genetic, and/or
environmental- that are potentially involved in the patho-
genesis of MC [11,12,79,82-84]. These factors, alone or in
combination, may trigger two multistep pathogenetic
processes, not mutually exclusive, responsible for MC and
other HCV-related disorders. The first one produces a
'benign' poly-olygoclonal B-lymphocyte proliferation
responsible for organ- and non-organ-specific autoim-
mune disorders, including the immune-complex-medi-
ated cryoglobulinemic vasculitis; the second one is
characterized by different oncogenetic alterations, which
ultimately may lead to malignant complications [11,82].
Comparable pathogenetic mechanisms could be also
hypothesized for HCV-negative MC, this intriguing clini-
cal subset might be correlated to other infectious agents or
associated to some well-known autoimmune/rheumatic
or lymphoproliferetive disorders (Fig. 5, 6) [13]. Th1-
mediated tissue alterations are probably responsible for
some endocrine disorders, i.e. diabetes type 2 and thyroid
dysfunction, in HCV-associated MC patients [57]. Our
preliminary data suggest that HCV infection of thyrocytes,
as well as of beta cells, may upregulate CXCL10 gene
expression and secretion (as shown in human hepato-
cytes); the consequent recruitment of Th1 lymphocytes
that secrete IFN-γ and TNF-α may in turn induce CXCL10
secretion by infected cells, thus perpetuating the immune
cascade responsible for these endocrine disorders. All the
above pathogenetic mechanisms could be also hypothe-
sized for HCV-negative MC, this intriguing clinical subset
might be correlated to other infectious agents or associ-
ated to some well-known autoimmune/rheumatic or lym-
phoproliferetive disorders (Fig. 5, 6) [13].
MC with or without overt clinical syndrome has been
reported in patients with a great number of infectious
agents, usually as anecdotally observations [9]. A signifi-
cant prevalence of MC has been observed in patients with
human immunodeficiency virus (HIV) infection, with
and without HCV co-infection [85]. HIV alone may exert
a continuous antigenic stimulation of B-lymphocytes;
these latter may be responsible for type III MC production
earlier in the course of HIV infection. In some patients the
B-cell disorder may evolve to monoclonal MC with typical
clinical syndrome. As observed for HCV infection, the
prevalence of other virus-related MC seems to show a var-
iable prevalence among patient's series from different geo-
graphical areas [86]. Moreover, a number of clinico-
epidemiological studies revealed a heterogeneous distri-
bution of different HCV-related extra hepatic manifesta-
tions, including some autoimmune disorders such as
'primary' Sjogren's syndrome [87-98].
Cryoglobulinemic syndrome may share a number of etio-
pathogenetic events and clinical features with both
autoimmune diseases such as autoimmune hepatitis, Sjö-
gren's syndrome, and polyarthritis, and B-cell lymphomas
[3,11,12,25,28,85-100]. Therefore, a differential diagno-
sis should be carefully done in all patients with MC syn-
drome (Fig. 7, see also the paragraph 'differential
diagnosis'); a correct disease classification may decisively
affect the overall clinico-therapeutic approach and prog-
nosis.
Diagnostic methods
There are no available diagnostic criteria for MC; in 1989
the Italian Group for the Study of Cryoglobulinemias has
proposed preliminary criteria for MC classification [101].
A revised version of these criteria (Table 3), including clin-
ico-pathological and virological findings, has been succes-
sively proposed [3]. Circulating mixed cryoglobulins, low
C4, and orthostatic skin purpura are the hallmarks of the
disease; moreover, leukocytoclastic vasculitis, involving
medium- and, more often, small-sized blood vessels (arte-
rioles, capillaries, and venules) is the typical pathological
finding of involved tissues. It is easily detectable by means
of skin biopsy of recent vasculitic lesions (within the first
24–48 hours) [3,11,12,25].
The detection of serum mixed (IgG-IgM) cryoglobulins is
necessary for a correct classification of MC syndrome
(Table 3, Fig. 1). Unfortunately, there are no universally
accepted methodologies for cryoglobulin measurements,
but simple standardized indications are often sufficient
for testing cryoglobulinemia [3,9,23]. Since cryoglobulins
present a high thermal instability, the measurement of Ig
cryoprecipitate should be performed immediately in the
same place where the blood is sampled. For a correct eval-
uation of serum cryoglobulins, it is necessary to avoidPage 8 of 17
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room temperature. For this purpose, the first steps (blood
sampling, clotting, and serum separation by centrifuga-
tion) should be always carried out at 37°C and the cry-
ocrit determination and cryoglobulin characterization at
4°C (after 7 days). The serum with cryoglobulins should
be tested for reversibility of the cryoprecipitate by rewarm-
ing an aliquot at 37°C for 24 hours. Moreover, cryocrit
determinations (percentage of packed cryoglobulins
referred to total serum after centrifugation at +4°C; Fig. 1)
should be done on blood samples without anticoagula-
tion to avoid false-positive results due to cryofibrinogen
or heparin-precipitable proteins. Without the above rela-
tively simple precautions, not only will the quantities of
cryoglobulins measured be incorrect, but the test may
completely fail to even detect cryoglobulins.
After isolating and washing the cryoprecipitate, the iden-
tity of cryoglobulin components can be determined by
immunoelectrophoresis or immunofixation. These analy-
sis must be performed at 37°C to avoid precipitation and
hence loss of the cryoglobulin during the procedures.
More sophisticated methodologies, such immunoblotting
or two-dimensional polyacrylamide gel electrophoresis,
can be proposed for laboratory investigations [102-104].
While the detection of serum cryoglobulins is fundamen-
tal for the diagnosis of MC, the levels of serum cryoglob-
ulins usually do not correlate with the severity and
prognosis of the disease [3,11,12,24,25]. Very low levels
of cryocrit, often difficult to quantify, can be associated
with severe and/or active cryoglobulinemic syndrome; on
the contrary, high cryocrit values may characterize a mild
or asymptomatic disease course. In rare cases, very high
cryocrit levels, possibly associated to cryogel phenome-
non, can be associated to classical hyperviscosity syn-
drome [24,25,27]. On the contrary, a sudden decrease or
disappearance of serum mixed cryoglobulins, with or
without abnormally high levels of C4, can be regarded as
alarming signal of complicating B-cell malignancy [45].
Table 4 summarizes the clinico-serological work-up at
patient's first evaluation in order to correctly classify the
MC syndrome and to identify possible overlapping disor-
ders (see next paragraph), and/or comorbidities. The prev-
alence of these latter, in particular atherosclerosis, may be
correlated with the disease duration, as well as with cumu-
lative side effects of prolonged treatments. Moreover, the
diagnosis and monitoring of the major MC manifesta-
tions is fundamental for timely treatments, especially for
life-threatening liver, renal, and/or neoplastic complica-
tions [3,11,12,24,25].
Differential diagnosis
The term 'essential' MC was originally referred to autono-
mous disease when other well known systemic, infectious
or neoplastic disorders have been ruled out by means of a
wide clinico-serological work-up [5]. However, in some
patients a definite diagnosis may be difficult because of
the clinical polymorphism of the disease. Moreover, the
association of MC with HCV infection may further com-
plicate the differential diagnosis with other immunologi-
cal HCV-related disorders: there is a frequent clinico-
pathological overlapping among different HCV-related
disorders. Cryoglobulinemic syndrome can represent a
crossroads between some autoimmune diseases (autoim-
mune hepatitis, Sjögren's syndrome, polyarthritis,
glomerulonephritis, thyroiditis, type 2 diabetes, etc.) and
malignancies (B-cell lymphomas, hepatocellular carci-
noma) [3,11,12,25,28,87-98]. It is possible to observe in
Differential diagnosis between mixed cryoglobulinemia and oth  autoimmune-lymphoproliferative disorders in the set-ting of HCV infectionFi u  7
Differential diagnosis between mixed cryoglobuline-
mia and other autoimmune-lymphoproliferative dis-
orders in the setting of HCV infection. Mixed 
cryoglobulinemia (MC) syndrome, primary Sjögren's syn-
drome (pSS), and rheumatoid arthritis (RA) show a clinico-
pathological overlap, including the possible association with 
HCV infection. The following parameters may be usefully 
employed for a correct differential classification/diagnosis: 
pSS shows typical histopathological pattern of salivary gland 
involvement and specific autoantibodies (anti-RoSSA/LaSSB), 
which are rarely found in MC patients; conversely, cutaneous 
leukocytoclastic vasculitis, visceral organ involvement 
(glomerulonephritis, hepatitis), low C4, and HCV infection, 
are typically found in MC. Moreover, erosive symmetrical 
polyarthritis and serum anti-cyclic citrullinated peptide anti-
bodies (anti-CCP) characterize classical RA. Finally, B-cell 
non-Hodgkin's lymphoma (B-NHL) may complicate these dis-
eases, more frequently MC and SS. The appearance of B-
NHL can be timely suspected by careful clinico-serological 
monitoring and diagnosed by bone marrow/lymph node biop-
sies and total body CT scan. RF: rheumatoid factor. (modified 
from [25]. Ferri C and Mascia MT, Curr Opin Rheumatol 2006, 
18: 54–63, with permission from Lippincott Williams & 
Wilkins).Page 9 of 17
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ciated hepatitis to various extrahepatic manifestations
(arthralgias, sicca syndrome, Raynaud's phenomenon, RF
positivity, etc.), and ultimately to overt MC syndrome
with typical clinico-serological manifestations. In only a
minority of MC patients a malignancy may develop, gen-
erally after a long lasting follow-up period
[3,11,12,24,25]. Therefore, a careful patient evaluation is
necessary for a correct diagnosis of MC syndrome, partic-
ularly with regards to other RF-positive, systemic rheu-
matic disorders such as rheumatoid arthritis (RA) and
primary Sjögren's syndrome (pSS) (Fig. 7).
While arthralgias are one of the most frequent symptoms,
clear signs of sinovitis are quite rare. Generally, patients
develop mild, non-erosive oligoarthritis [28,90], often
sensitive to low doses of corticosteroids with or without
hydroxychloroquine. In contrast, a rheumatoid-like pol-
yarthritis is more frequent in patients with HCV-related
hepatitis without MC syndrome [28]. In patients with
HCV-associated MC and symmetrical, erosive polyarthri-
tis the diagnosis of overlapping MC/RA syndrome can be
suspected. In these cases, the detection of serum anti-
cyclic citrullinated peptide antibodies, markers of classical
RA, may represent a useful diagnostic tool [91,92].
Almost half MC patients complain of sicca syndrome;
however, only a few cases meet the current criteria for the
classification of pSS. MC and pSS may share various
symptoms: xerostomia and/or xerophthalmia, arthralgias,
Table 3: Proposed criteria for the classification of mixed cryoglobulinemia (MC) patients.
Criteria Serological Pathological Clinical
major mixed cryoglobulins
low C4
leukocytoclastic vasculitis purpura
minor rheumatoid factor +
HCV +
HBV +
clonal B-cell infiltrates
(liver and/or bone marrow)
chronic hepatitis
MPGN
peripheral neuropathy
skin ulcers
definite mixed cryoglobulinemia syndrome:
a) serum mixed cryoglobulins (± low C4) + purpura + leukocytoclastic vasculitis
b) serum mixed cryoglobulins (± low C4)+ 2 minor clinical symptoms
+ 2 minor serological/pathological findings
essential or secondary mixed cryoglobulinemia:
absence or presence of well-known disorders (infectious, immunological or neoplastic)
HCV+ or HBV+: markers of hepatitis C virus or hepatitis B virus infection (anti-HCV ± HCV RNA; HBV DNA or HBsAg); MPGN: 
membranoproliferative glomerulonephritis.
Table 4: Clinico-diagnostic assessment of mixed cryoglobulinemia (MC) syndrome
Clinical and serological work-up at patient's first evaluation
• past clinical history, physical examination
• chest x-ray, EKG, abdominal US, blood chemistry & urinalysis
• cryoglobulin detection and characterization (see Tab. 1)
• RF, C3–C4, ANA, anti-ENA, ANCA, ASMA, AMA, anti-LKM1, others auto-Ab
• virological markers: HCV (genotyping), HBV, others
• evaluate possible comorbidities (cardiovascular, endocrine/metabolic, etc.)
• MC classification (definite, essential, secondary): see Tab. 3
Diagnosis & monitoring of major MC complications
• chronic hepatitis, cirrhosis, hepatocellular carcinoma: monitoring (every 6–12 month) of ALT, AP & liver US (biopsy, CT scan)
• glomerulonephritis: monitoring of urinalysis & serum creatinine (kidney US, biopsy)
• peripheral neuropathy: clinical monitoring; EMG
• skin ulcers: exclusion of vascular comorbidities (A-V Doppler evaluation)
• sicca syndrome: differential diagnosis with primary SS (see Fig. 7)
• arthritis: differential diagnosis with RA (see Fig. 7)
• thyroid involvement: hormones, auto-Ab, neck US, fine-needle aspiration
• B-cell lymphoma: clinical monitoring; bone marrow/lymph node biopsies, total body CT scan
Abbreviations: F: rheumatoid factor; ANA: antinuclear antibodies; anti-ENA: anti-extractable nuclear antigen antibodies; AMA: antimitochondrial 
antibodies; ASMA: anti-smooth muscle antibodies; anti-LKM1: anti-liver/kidney microsome type 1 antibodies; ALT: alanine aminotransferase; AP: 
alkaline phosphatase; US: ultrasonography; CT: computed tomography; EMG: electromyography; RA: rheumatoid arthritis; SS: Sjögren's syndromePage 10 of 17
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complication with B-cell lymphoma [3,11,12,25,87,93-
98]. However, a careful patient clinical assessment is usu-
ally sufficient for a correct diagnosis in the large majority
of cases by considering some important findings: his-
topathological alterations of salivary glands and specific
autoantibody pattern (anti-RoSSA/LaSSB) of pSS are
rarely found in MC patients; conversely, HCV infection,
cutaneous leukocytoclastic vasculitis, and visceral organ
involvement (renal, liver) are seldom recorded in primary
Sjögren's syndrome (Fig. 7). Given the above considera-
tions, it has been recently proposed that the presence of
HCV infection per se should be considered exclusion crite-
ria for the classification of pSS [99,100]. In rare cases in
which the differential diagnosis may result very difficult,
particularly in HCV-negative individuals, it might be cor-
rect to classify the disorder as overlap syndrome. How-
ever, patients with MC/pSS overlap syndrome are often
characterized by more severe clinico-prognostic evolu-
tion; they show a significant low rate of anti-RoSSA/LaSSB
along with a high prevalence of mixed cryoglobulinemia,
hypocomplementemia, systemic autoimmune manifesta-
tions, and complicating lymphomas (94, 97, 98). In the
clinical practice, this particular condition could be better
regarded as vasculitic syndrome with relevant implica-
tions on the patient monitoring and treatment [11,24,25].
Finally, autoimmune hepatitis, the old 'lupoid' hepatitis,
may be associated to HCV infection, mainly in the same
countries where HCV-associated MC is more frequently
found [88]. Moreover, it may share with MC syndrome a
number of extrahepatic symptoms, including serum
mixed cryoglobulins [89]. The differential diagnosis
between these two conditions may be problematic: some
typical features of MC (leukocytoclastic vasculitis,
hypocomplementemia, glomerulonephritis), as well as
the presence of serum autoantibodies commonly found in
autoimmune hepatitis (anti-smooth muscle antibodies)
can be taken into account.
Management
Considering its complex etiopathogenesis and clinical
polymorphism, the treatment of MC syndrome is particu-
larly challenging. For a correct therapeutic approach, three
important factors (Fig. 6), namely, the HCV infection, the
presence of autoimmune disorder, and the possible neo-
plastic complications should be considered [3,25]. Fol-
lowing the main steps of the etiopathogenetic process,
from HCV infection to B-lymphocyte proliferation, and
lastly to cryoglobulinemic vasculitis (Fig. 8), the disease
can be treated at different levels by means of etiologic,
pathogenetic, and/or symptomatic therapies. Since HCV
represents the main causative factor of the disease by
exerting a chronic stimulus on the immune-system [3,8-
12,14,24], an attempt at HCV eradication by alpha-inter-
feron treatment should be done in all cases of HCV-asso-
ciated MC [3,11,12,24,105-109]. However, the beneficial
effect observed with this drug is often transient and possi-
bly associated with important immune-mediated side
effects such as peripheral sensory-motor neuropathy, thy-
roiditis, and rheumatoid-like polyarthritis [51-54]. Proba-
bly, in predisposed subjects alpha-interferon (which is
both antiviral and immunomodulating agent) can trigger
or exacerbate some pre-existing, often subclinical, symp-
toms. Unfortunately, there are no available parameters for
predicting this harmful complication; thus, alpha-inter-
feron therapy should be avoided at least in those patients
with clinically evident peripheral neuropathy. On the
whole, the usefulness of alpha-interferon treatment in MC
patients is limited by the low rate of responders and fre-
quent side effects. The association of alpha-interferon and
ribavirin might achieve the eradication of HCV infection
in a higher number of treated subjects, even if the long-
term effects are inconstant and often unpredictable
[3,11,12,24,105-114]. After careful patient's evaluation of
contraindications and/or possible side effects, a standard
treatment with alpha-interferon and ribavirin [111]
should be attempted in MC patients with prevalent clin-
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Treatment of mixed cryoglobulinemia (MC) syn-
drome according to the etiopathogenesis of the dis-
ease (1). MC is the result of a multistep process including 
three main clinico-pathological levels: 1) chronic HCV infec-
tion, 2) B-lymphocyte proliferation, and 3) immune-complex-
mediated vasculitis (cryoglobulinemic vasculitis). Following 
the cascade of events leading from HCV infection to overt 
vasculitic syndrome, we can treat the patients at different 
levels by means of etiologic, pathogenetic, and/or sympto-
matic therapies (see also Fig. 6, 9, and 10). RF: rheumatoid 
factor; CIC: circulating immune-complexes; LAC-diet: low-
antigen-content diet. (modified from [25]: Ferri C and Mascia 
MT, Curr Opin Rheumatol 2006, 18: 54–63, with permission 
from Lippincott Williams & Wilkins).Page 11 of 17
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Controlled clinical trials might establish the actual useful-
ness of antiviral therapy in HCV-associated MC and better
evaluate the predictive markers of response to treatment
(HCV genotypes, host HLA alleles?). Hopefully, with the
rapid growth of molecular biology a vaccine against HCV
might be available in the near future. A vaccine-based
therapy [115] with recombinant HCV proteins in HCV-
infected individuals could be able to prevent the progres-
sion of viral infection and possibly to interrupt the self-
perpetuating autoimmune mechanism underlying the
MC.
In patients with 'essential' MC the immunosuppressive
treatment, i.e. cyclophosphamide or rituximab, is still the
first-line intervention (Fig. 9, 10). For HCV-associated
MC, immunomodulating/immunosuppressive treat-
ments should be considered, especially in patients with
more severe complications. These treatments include ster-
oids, low-antigen-content (LAC) diet, plasma exchange,
and immunosuppressors [3,11,12,24,116-122]. In partic-
ular, both traditional plasma exchange and double-filtra-
tion plasma exchange are able to markedly reduce the
levels of circulating immune-complex, especially the cry-
oglobulins [24,121,122]. Oral cyclophosphamide (50–
100 mg/day for 2–6 weeks) during the tapering of apher-
etic sessions can reinforce the beneficial effect of plasma
exchange; moreover, it can prevent the rebound phenom-
enon that may be observed after the aphaeresis discontin-
uation [24]. Plasma exchange is particularly useful in
severe MC complications such as active membranoprolif-
erative glomerulonephritis (Fig. 8, 9, 10).
LAC-diet is a particular dietetic treatment that can
improve the clearance circulating immune-complexes by
restoring the activity of the reticulo-endothelial system,
overloaded by large amounts of circulating cryoglobulins
[122,123]. LAC-diet has been designed to reduce the
input of alimentary macromolecules crossing the mucosal
Therapeutic strategy according to activity/severity of mixed cryoglob l nemia (MC) syn rome (2)Figure 9
Therapeutic strategy according to activity/severity of 
mixed cryoglobulinemia (MC) syndrome (2). Thera-
peutic strategy of mixed cryoglobulinemia (MC) syndrome 
(or cryoglobulinemic vasculitis) should be decided on the 
basis of the activity/severity of clinical symptoms and tailored 
for the single patient: in asymptomatic patients a careful 
monitoring is often sufficient; in those with moderate-severe 
manifestations, mainly in the presence of active chronic hepa-
titis, an attempt to eradicate the HCV infection should be 
carried out; particularly severe, rapidly progressive complica-
tions must be treated with more aggressive treatments, as in 
other systemic vasculitides. Sequential treatment schedules 
can be employed in individuals with particularly aggressive 
manifestations and/or partial response (clinical, pathological, 
or virological) to traditional treatments (see also Fig. 8 and 
10). Purp.: purpura; weak.: weakness; arthr.: arthralgias; CPX: 
cyclophosphamide; CS: corticosteroids; LAC-diet, low-anti-
gen-content diet; MPGN, membranoproliferative glomeru-
lonephritis; peg-IFN: pegylated interferon-alpha; RIBA: 
ribavirin.
Flow chart of therapeutic strategies according to activity/severity of mixed cryoglobulinemia (MC) sy dr me (3)igure 10
Flow chart of therapeutic strategies according to 
activity/severity of mixed cryoglobulinemia (MC) 
syndrome (3). HCV-positive MC patients with moderate-
severe manifestations, mainly in the presence of active 
chronic hepatitis, antiviral treatment with pegylated inter-
feron-alpha (peg-IFN) + ribavirin (RIBA) can be tried after 
exclusion of possible contraindications. In non-responders or 
in those with partial response (virological), a treatment with 
rituximab (RTX) can be proposed (a). Conversely, in HCV+ 
MC patients usefully treated with rituximab or other anti- 
inflammatory/immunosuppressive therapies, an attempt to 
eradicate HCV infection can be done (b). Finally, combined 
high dose corticosteroids (CS), plasma exchange (PE), and 
cyclophosphamide (CPX) are the first line treatment in life-
threatening, rapidly progressive complications in both HCV+ 
and HCV- cryoglobulinemic vasculitis (see also Fig. 8 and 9). 
LAC-diet: low-antigen-content diet.Page 12 of 17
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and eggs, present a potential antigenic activity, and conse-
quently might be involved in the pathogenesis of some
diseases in humans. The reduction of the alimentary input
of macromolecules directed to mononuclear phagocytic
system may improve its function in those conditions char-
acterized by abnormal endogenous production of
immune-complexes responsible for organ damage, i.e.
mixed cryoglobulinemia and other immune-complex
mediated diseases. An impaired function of mononuclear
phagocytic system has been also demonstrated in patients
with IgA nephropathy [123]. Given the above pathoge-
netic considerations, LAC-diet has been usefully
employed in patients with clinically mild MC symptoms
and IgA nephropathy (reduction of 24-hour proteinuria).
Usually, LAC-diet and/or low dosage of steroids (6-
methyl-prednisolone 2–4 mg/day) may be sufficient to
improve mild manifestations (arthralgias, sporadic pur-
pura, etc.) of the MC (Fig. 8, 9, 10); patients with mild-
moderate symptoms, such as palpable purpura, are partic-
ularly sensitive to the smallest variations of daily steroid
dosage (1–2 mg).
In clinical practice, MC treatment should be tailored for
the single patient according to the severity of clinical
symptoms (Fig. 9, 10). Therefore, patients with severe vas-
culitic manifestations must be promptly treated with high
doses of steroids and/or plasma exchange and/or cyclo-
phosphamide or rituximab. Some recent clinical studies
suggested that sequential or combined antiviral/immuno-
suppressive treatment could represent a rather useful ther-
apeutic strategy [124,125]. The rationale of such
aggressive therapies could be particularly indicated in MC
patients with major clinical manifestations and partial/
transitory remission after standard treatments
[25,124,125]. On the contrary, clinically asymptomatic
patients usually do not need any treatment, even in the
presence of high levels of cryocrit. In all cases, a careful
clinical monitoring of the disease is mandatory, with par-
ticular attention to neoplastic complications. Preliminary
studies suggested the synergic affect of some therapies in
association with antiviral treatment, namely the
cyclosporine A or tumor necrosis factor inhibitors, in the
setting of chronic hepatitis type C [126-128]. These agents
may contribute to viral clearance and/or to improve the
immune-mediated hepatic and extrahepatic inflamma-
tory manifestations; future clinical trials might evaluate
their potential usefulness even in MC, possibly in selected
patient subsets.
Prognosis
The natural history of MC is not predictable and strongly
depends on concomitant diseases and complications and
response to treatment. Morbidity due specifically to cry-
oglobulinemia may also be significant (infections, cardio-
vascular diseases, progressive renal failure, advanced
neuropathy). The overall prognosis is worse in patients
with renal disease, liver failure, lymphoproliferative dis-
ease, and malignancies. Mean survival is estimated to be
approximately 50–60% at 10 years after diagnosis [24].
Careful monitoring of life-threatening MC complications
(mainly nephropathy, widespread vasculitis, and B-cell
lymphoma or other malignancies) should be carried out
in all MC patients.
Unresolved questions
MC was first described as distinct disorder in 1966 [5]; 25
years later the discovery of the strong association between
MC and HCV infection [3,11,12,25,70] represented a
decisive contribute for a better understanding of the etio-
pathogenetic mechanisms responsible for the disease, and
consequently for an adequate therapeutic strategy.
However, the following points remain still to be clarified:
1- Since the etiopathogenesis of HCV-associated MC syn-
drome is a multifactorial and multistep process, two
important aspects need further investigations: a) HCV
may represent the simple triggering factor or it could also
contribute to self-perpetuating mechanism of the disease:
b) nature and role of other etiopathogenetic co-factors;
2- The etiopathogenesis of 'essential' MC syndrome;
3- The actual role of HCV eradication on the natural his-
tory of HCV-associated MC syndrome;
4- The usefulness of sequential or combined antiviral/
immunesuppressive treatments compared to traditional
therapeutic approach.
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